To gain insights, we performed systematic transcriptomic and whole-cell proteomic analyses of XLP-2 versus healthy control B cells at Day 7 after EBV infection or CD40L/IL-21 stimulation. The gene discussed is IL21; the disease is Epstein-Barr virus infection.